Table 4.

Correlation between benznidazole serum concentrations and treatment interruption, sex, other conditions, and concomitant drug use

Time point (days)	Median benznidazole serum concn in μg/ml (IQR) [no. of patients] and associated P valuea
	Treatment completed			Sex			Other diseases			Concomitant drug use
	Yes	No	P	Male	Female	P	No	Yes	P	No	Yes	P
15	6.5 (1.8) [38]	5.2 (3.4) [6]	0.0811	6.4 (1.7) [14]	6.0 (2.0) [31]	0.8445	6.57 (2.0) [30]	5.7 (1.7) [15]	0.3005	6.5 (2.1) [31]	5.6 (1.6) [14]	0.2918
30	6.18 (1.86) [39]	4.4 (4.8) [3]	0.0919	6.3 (1.7) [15]	6.1 (2.2) [28]	0.3589	6.2 (2.3) [28]	5.9 (1.4) [15]	0.8186	6.3 (1.4) [29]	5.3 (1.2) [14]	0.1327
45	6.3 (1.99) [37]	4.8 (2.2) [2]	0.1613	6.0 (2.2) [15]	6.3 (2.2) [24]	0.6236	6.1 (1.8) [25]	6.3 (2.6) [14]	0.7035	6.1 (1.8) [25]	6.4 (3–0) [14]	0.8148
60	5.7 (1.7) [37]			5.9 (2.9) [15]	5.3 (1.7) [22]	0.8649	5.9 (2.3) [25]	5.2(1.7) [12]	0.2363	5.9 (2.0) [24]	5.0 (1.9) [13]	0.3318

^aStatistical significance was set at P < 0.0125.